Company intelligence / Profile preview
Dexlevo
Gangnam-gu, Seoul, South Koreadexlevo.co.kr ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Dexlevo has developed GOURI—the world’s first fully solubilized liquid polycaprolactone (PCL) injectable. GOURI has CE certification for use as a medical device/filler in Europe and other regions. Clinical trials are underway to obtain regulatory approval in South Korea. The product promotes natural collagen regeneration throughout the face with minimal invasiveness and without forming lumps or nodules.
- Therapeutic areas
- Dermatology
- Modalities
- BiologicPolymer-based injectable (specifically Polycaprolactone-based)Medical device
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Hugel (MOU signed)Multiple global distribution companies across Spain, UAE, Saudi Arabia, North Africa/MENA region
Beyond the preview
Go deeper on Dexlevo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dexlevo.